Acrivon Therapeutics (NASDAQ:ACRV) Issues Earnings Results

Acrivon Therapeutics (NASDAQ:ACRV – Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.02, FiscalAI reports.

Acrivon Therapeutics Stock Up 0.7%

Shares of NASDAQ ACRV traded up $0.01 on Monday, hitting $1.46. The company had a trading volume of 340,607 shares, compared to its average volume of 791,367. Acrivon Therapeutics has a 12-month low of $1.27 and a 12-month high of $3.56. The firm has a market capitalization of $62.57 million, a P/E ratio of -0.78 and a beta of 1.96. The business has a 50 day moving average of $1.83 and a two-hundred day moving average of $1.75.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on ACRV shares. Weiss Ratings raised Acrivon Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 9th. Wall Street Zen cut Acrivon Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 7th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Acrivon Therapeutics in a research report on Wednesday, November 11th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.50.

View Our Latest Report on ACRV

Insider Activity at Acrivon Therapeutics

In related news, CEO Peter Blume-Jensen sold 14,036 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $2.21, for a total transaction of $31,019.56. Following the sale, the chief executive officer directly owned 2,230,052 shares in the company, valued at approximately $4,928,414.92. This trade represents a 0.63% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 17,345 shares of company stock worth $37,578. Company insiders own 10.50% of the company’s stock.

Acrivon Therapeutics Company Profile

(Get Free Report)

Acrivon Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for cancer. Its research focuses on identifying treatments for patients whose tumors have molecular characteristics that may make them more likely to respond to a particular therapy. The company’s Acrivon Predictive Precision Proteomics (AP3) platform analyzes protein activity in tumor samples to identify these characteristics and help guide patient selection. Acrivon’s clinical-stage candidate ACR-368 is a small-molecule inhibitor of the CHK1 and CHK2 enzymes being studied in solid tumors.

Read More

Earnings History for Acrivon Therapeutics (NASDAQ:ACRV)

Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.